Exemestane: observed
43 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyRecruitingNCT04476485Report a problem
- Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.CompletedNCT06086340Results postedReport a problem
- Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast CancerCompletedNCT01896050Results postedReport a problem
- Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer PatientsCompletedNCT01814397Results postedReport a problem
- A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ PatientsTerminatedNCT01305239Results postedReport a problem
- Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast CancerTerminatedNCT01239745Results postedReport a problem
- Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer PatientsTerminatedNCT01155063Results postedReport a problem
- Effects of Exemestane on Bone StrengthCompletedNCT01144468Results postedReport a problem
- A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast CancerTerminatedNCT01121549Results postedReport a problem
- Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)CompletedNCT01050634Results postedReport a problem
- Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerCompletedNCT01047358Results postedReport a problem
- Special Investigation For Patients With Renal And/Or Hepatic Disorders On AromasinCompletedNCT00932165Results postedReport a problem
- An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With AromasinTerminatedNCT00776659Results postedReport a problem
- A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingNCT06495164Report a problem
- A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentCompletedNCT06311383Report a problem
- Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.CompletedNCT05789771Report a problem
- Pilot Observational Study Examining the Effect of Endocrine Therapy on AgingCompletedNCT05700006Report a problem
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/LetrozoleCompletedNCT05635357Report a problem
- Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast CancerStatus unknownNCT04891731Report a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081Report a problem
- First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingNCT04767594Report a problem
- Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastStatus unknownNCT04666805Report a problem
- Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast CancerStatus unknownNCT04389424Report a problem
- Breast Cancer Treatment Based on Organ-like CultureStatus unknownNCT03925233Report a problem
- 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AICompletedNCT03695341Report a problem
- 500mg Fulvestrant Versus Exemestane in MBCCompletedNCT03575260Report a problem
- Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer PatientsCompletedNCT03541863Report a problem
- Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast CancerStatus unknownNCT02875951Report a problem
- Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer PatientsStatus unknownNCT02765373Report a problem
- Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyCompletedNCT02753686Report a problem
- Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast CancerCompletedNCT02023359Report a problem
- Prediction of Everolimus-induced Interstitial Lung DiseaseCompletedNCT01978171Report a problem
- Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal DatabaseCompletedNCT01937052Report a problem
- Metabolizing Enzyme Genotype Versus Exemestane Metabolism ProfilesCompletedNCT01626144Report a problem
- Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer SurvivorsCompletedNCT01272570Report a problem
- A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerCompletedNCT01171417Report a problem
- Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerCompletedNCT00719966Report a problem
- Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3CompletedNCT00688246Report a problem
- Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast CancerCompletedNCT00516698Report a problem
- Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or AnastrozoleCompletedNCT00316836Report a problem
- Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast CancerCompletedNCT00283608Report a problem
- Aromatase Inhibitor Clinical TrialStatus unknownNCT00228956Report a problem
- Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast CancerCompletedNCT00090974Report a problem